Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gene engineering and combinatorial approaches with other cancer immunotherapy agents may confer capabilities enabling full tumor rejection by adoptive T cell therapy (ACT). The provision of proper costimulatory receptor activity and cytokine stimuli, along with the repression of inhibitory mechanisms, will conceivably make the most of these treatment strategies. In this sense, T cells can be genetically manipulated to become refractory to suppressive mechanisms and exhaustion, last longer and differentiate into memory T cells while endowed with the ability to traffic to malignant tissues. Their antitumor effects can be dramatically augmented with permanent or transient gene transfer maneuvers to express or delete/repress genes. A combination of such interventions seeks the creation of the ultimate bionic T cell, perfected to seek and destroy cancer cells upon systemic or local intratumor delivery.

Original publication

DOI

10.1038/s41423-020-0464-1

Type

Journal article

Journal

Cellular & molecular immunology

Publication Date

06/2020

Volume

17

Pages

576 - 586

Addresses

Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain. ietxeberria@alumni.unav.es.

Keywords

T-Lymphocytes, Animals, Humans, Neoplasms, Genetic Engineering, Bionics, Signal Transduction, Immunity